2 transcripts
ALKS
Earnings call transcript
NASDAQ
2024 Q1
1 May 24
adverse events assessed as related to study drug were mild transient resolved without treatment, no severe or serious AEs were reported
ALKS
Earnings call transcript
NASDAQ
2023 Q4
15 Feb 24
assessments just as a matter of precaution to make sure we understand, if there are on-target visual effects at any dose, that's something we want
- Prev
- 1
- Next